Market closed

CytomX/$CTMX

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About CytomX

CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Ticker

$CTMX

Sector

Health Care

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

South San Francisco, United States

Employees

121

Website

www.cytomx.com

CytomX Metrics

BasicAdvanced

$66M

5.21 $0.16

1.06 -

Price and volume

Market cap

$66M

Beta

1.06

52-week high

$5.85

52-week low

$0.81

Average daily volume

1.6M

Financial strength

Current ratio

1.042

Quick ratio

1.014

Long term debt to equity

-23.862

Total debt to equity

-45.186

Management effectiveness

Return on assets (TTM)

2.33%

Return on equity (TTM)

-37.03%

Valuation

Price to earnings (TTM)

5.207

Price to revenue (TTM)

0.554

Price to book

-2.81

Price to tangible book (TTM)

-2.63

Price to free cash flow (TTM)

-0.79

Growth

Revenue change (TTM)

33.66%

Earnings per share change (TTM)

-210.88%

3-year revenue growth (CAGR)

24.12%

3-year earnings per share growth (CAGR)

-48.92%

What the Analysts think about CytomX

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for CytomX stock.

CytomX Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

CytomX Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

CytomX News

AllArticlesVideos

CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update

GlobeNewsWire·1 week ago

CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference

GlobeNewsWire·2 months ago

CytomX Therapeutics, Inc. (CTMX) Q3 2024 Earnings Call Transcript

Seeking Alpha·2 months ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $CTMX

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for CytomX stock?

CytomX (CTMX) has a market cap of $66M as of January 15, 2025.

What is the P/E ratio for CytomX stock?

The price to earnings (P/E) ratio for CytomX (CTMX) stock is 5.21 as of January 15, 2025.

Does CytomX stock pay dividends?

No, CytomX (CTMX) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next CytomX dividend payment date?

CytomX (CTMX) stock does not pay dividends to its shareholders.

What is the beta indicator for CytomX?

CytomX (CTMX) has a beta rating of 1.06. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.